Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE

医学 不利影响 临床试验 梅德林 皮肤病科 外科 内科学 政治学 法学
作者
Geoffrey Alan Watson,Zachary Veitch,Daniel Shepshelovich,Zhihui Amy Liu,Anna Spreafico,Albiruni R. Abdul Razak,Philippe L. Bédard,Lillian L. Siu,Lori M. Minasian,Aaron R. Hansen
出处
期刊:British Journal of Cancer [Springer Nature]
卷期号:127 (9): 1629-1635 被引量:4
标识
DOI:10.1038/s41416-022-01926-z
摘要

Adverse event (AE) reporting in early-phase clinical trials is essential in determining the tolerability of experimental anticancer therapies. The patient-reported outcome version of the CTCAE (PRO-CTCAE) evaluates AE components such as severity and interference in daily life. The aim of this study was to correlate the grade of clinician-reported AEs with patients' reported experience of these toxicities using PRO-CTCAE. Patients with advanced solid tumours enrolled on Phase I clinical trials were surveyed using the PRO-CTCAE. Symptomatic AEs were recorded by physicians using the CTCAE. A logistic regression model was used to assess associations between CTCAE grade and PRO responses. Of 219 evaluable patients, 81 experienced a high-grade (3/4) clinician-reported symptom, and of these, only 32 (40%) and 26 (32%) patients concordantly reported these as either severe or very severe, and interfering with daily life either 'quite a bit' or 'very much', respectively. Of the 137 patients who experienced a low-grade (1/2) clinician-reported AE as their worst symptom, 98 (72%) and 118 (86%) patients concordantly reported these as either mild–moderate severity and minimally interfering with daily life, respectively. There was a statistically significant association between clinician-reported AE grade and interference. Interference scores were also associated with dose reductions. This is the first study to explore patient-reported severity and interference from symptomatic toxicities and compare clinician grading of the same toxicities. The study provided further evidence to support the added value of the PRO-CTCAE in Phase I oncology trials, which would make AE reporting patient-centred. Further work is needed to determine how this would affect the assessment of tolerability.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zSunday完成签到,获得积分10
刚刚
超人发布了新的文献求助10
1秒前
沛沛发布了新的文献求助10
1秒前
zzzz完成签到,获得积分10
1秒前
1秒前
chenwei发布了新的文献求助10
1秒前
1秒前
FeCl完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
LuoJiajun完成签到,获得积分10
2秒前
2秒前
tingting完成签到 ,获得积分10
2秒前
anna1992发布了新的文献求助10
3秒前
英姑的应助被attention采纳,获得30
3秒前
玩命的善若完成签到,获得积分10
3秒前
可燃斌完成签到,获得积分10
3秒前
小y完成签到,获得积分10
4秒前
sy完成签到,获得积分10
4秒前
4秒前
Z奋勇完成签到,获得积分10
4秒前
4秒前
欻欻欻完成签到,获得积分10
5秒前
ss的应助被YC采纳,获得10
5秒前
田様的应助被唐飒采纳,获得10
5秒前
风吹麦浪的应助被STP顶峰相见采纳,获得10
5秒前
5秒前
5秒前
5秒前
6秒前
学术小白w完成签到,获得积分10
6秒前
脆脆芝香香完成签到,获得积分10
6秒前
6秒前
星如繁花发布了新的文献求助10
7秒前
yorollh发布了新的文献求助10
7秒前
anzhiyuan发布了新的文献求助10
7秒前
昀离发布了新的文献求助10
7秒前
7秒前
悠悠小土豆完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167144
求助须知:如何正确求助?哪些是违规求助? 9559992
关于积分的说明 21753860
捐赠科研通 7758038
什么是DOI,文献DOI怎么找? 3429304
关于科研通互助平台的介绍 2553613
邀请新用户注册赠送积分活动 2474023